Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting coagulation.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Atrial fibrillation with embolization,Treatment of acute myocardial infarction (unstable angina, ST-elevation MI),As an anticoagulant in extracorporeal circuits and blood transfusions,Off-label: prevention of recurrent spontaneous abortion, disseminated intravascular coagulation
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous: Initial bolus of 5,000-10,000 units, followed by continuous infusion at 15-25 units/kg/hour. Subcutaneous: 5,000-10,000 units every 8-12 hours. Dose adjusted to maintain a PTT 1.5-2.5 times control.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
The terminal elimination half-life of heparin is dose-dependent: at 100 U/kg IV, approximately 60 minutes; at 400 U/kg, approximately 150 minutes. The half-life is prolonged in hepatic dysfunction and shortened in pulmonary embolism.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Heparin is primarily metabolized by the reticuloendothelial system (liver and spleen) via desulfation and depolymerization, with partial metabolism by the kidney. It is excreted in urine as unchanged drug and metabolites.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Heparin is primarily cleared by the reticuloendothelial system and the liver, where it undergoes desulfation and depolymerization. Renal excretion of intact heparin accounts for <10% of total clearance. Biliary/fecal elimination is negligible.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Heparin binds to antithrombin III (ATIII), heparin cofactor II, and other plasma proteins. Protein binding is high but variable (often reported as >90%) due to binding to ATIII and nonspecific binding.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
The apparent volume of distribution (Vd) is approximately 0.06 L/kg (range 0.04-0.07 L/kg). This low Vd reflects confinement to the vascular space.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Subcutaneous: approximately 20-30% due to binding to endothelial cells and macrophages. IV: 100%.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No specific dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, use with caution and monitor a PTT closely; consider dose reduction of 25-50%.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution, monitor a PTT; consider dose reduction of 25-50%. Child-Pugh Class C: Avoid use due to increased bleeding risk; if necessary, use with extreme caution and reduce dose by 50-75%.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Intravenous: Initial bolus 75-100 units/kg, then continuous infusion 20-25 units/kg/hour. Subcutaneous: 75-100 units/kg every 8 hours. Adjust to target anti-factor Xa level of 0.3-0.7 units/m L.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Elderly patients have reduced clearance; start with lower end of dosing range (e.g., initial bolus 5,000 units, infusion at 15-20 units/kg/hour) and monitor a PTT frequently due to increased risk of bleeding.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Heparin should not be used interchangeably with heparin lock flush or other heparin products. Fatal hemorrhage can occur. Monitor for thrombocytopenia and signs of bleeding. Heparin-induced thrombocytopenia (HIT) can lead to new thrombotic events.
None
Monitor for signs of bleeding, especially in patients with renal impairment, hypertension, or gastrointestinal lesions.,Heparin-induced thrombocytopenia (HIT) with thrombosis (HITT) can occur; discontinue if platelets fall significantly.,Use with caution in patients with bleeding disorders, recent surgery, or hypersensitivity to heparin.,Protamine sulfate should be available for reversal of overdose.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Uncontrolled active bleeding,History of heparin-induced thrombocytopenia (HIT) or hypersensitivity to heparin,Severe thrombocytopenia,When suitable blood coagulation tests cannot be performed at appropriate intervals
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No known food interactions. Maintain a consistent intake of vitamin K-rich foods if also on warfarin; otherwise, no dietary restrictions.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Heparin does not cross the placenta and is not associated with teratogenic risk. No increased risk of fetal malformations has been reported. First trimester: no known risk. Second trimester: no known risk. Third trimester: no known risk.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Heparin is not excreted into breast milk due to its high molecular weight and polarity. M/P ratio is not applicable. Considered compatible with breastfeeding.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy increases heparin clearance due to plasma volume expansion and enhanced renal function; may require higher doses and more frequent monitoring. Dose adjustments are individualized based on a PTT targets. No standard fixed dose adjustment; titrate to therapeutic a PTT range.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Monitor a PTT 6 hours after initiation and after dose changes; target 1.5-2.5 times control. Use weight-based dosing for therapeutic anticoagulation (e.g., 80 units/kg bolus then 18 units/kg/hour). Avoid IM injections due to hematoma risk. Reversal agent: protamine sulfate (1 mg per 100 units heparin). Check platelet count regularly for heparin-induced thrombocytopenia (HIT). Use with caution in renal impairment.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Report any unusual bleeding, bruising, or dark stools immediately.,Avoid aspirin, NSAIDs, and other blood thinners unless prescribed.,Use a soft toothbrush and electric razor to prevent cuts.,Inform all healthcare providers that you are on heparin.,Do not stop or change the dose without consulting your doctor.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting coagulation.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous: Initial bolus of 5,000-10,000 units, followed by continuous infusion at 15-25 units/kg/hour. Subcutaneous: 5,000-10,000 units every 8-12 hours. Dose adjusted to maintain a PTT 1.5-2.5 times control.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Heparin does not cross the placenta and is not associated with teratogenic risk. No increased risk of fetal malformations has been reported. First trimester: no known risk. Second . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.